Document Detail


Early initiation of statin therapy in acute coronary syndromes: a review of the evidence.
MedLine Citation:
PMID:  15788056     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Acute coronary syndromes (ACS), such as myocardial infarction and unstable angina, are leading causes of death in developed countries. The risk of recurrent adverse events, rehospitalization, and death remain high in the weeks to months following ACS. Large secondary prevention trials have shown that the initiation of statin therapy within 3-6 months after hospitalization for ACS decreases the risk of recurrent cardiovascular events and death. Although the precise mechanisms behind these clinical benefits are unknown, data from human and animal studies have implicated statins in inflammatory response modulation, plaque stability, thrombus formation, and endothelial function. Several observational studies have demonstrated cardiovascular mortality and morbidity benefits in patients with ACS who were placed on statins within hours to days of their event. Three recent prospective controlled trials confirmed these benefits and demonstrated that moderate doses of statins are safe when used in patients with ACS. We recommend the initiation of statin therapy in all ACS patients prior to hospital discharge.
Authors:
Matthew T Rondina; Joseph B Muhlestein
Related Documents :
210876 - Severity of coronary atherosclerosis related to lipoprotein concentration.
11427206 - Fibromuscular cap composition is important for the stability of established atheroscler...
18221106 - An update on the role of the quality of ldl in cardiovascular risk: the contribution of...
17601396 - Aggressive statin therapy for acute coronary syndromes.
6942806 - The efficacy of potassium-induced cardioplegia and topical hypothermia in the correctio...
20122596 - Predicting ischemic brain injury after intraoperative cardiac arrest during cardiac sur...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of interventional cardiology     Volume:  18     ISSN:  0896-4327     ISO Abbreviation:  J Interv Cardiol     Publication Date:  2005 Feb 
Date Detail:
Created Date:  2005-03-24     Completed Date:  2005-05-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8907826     Medline TA:  J Interv Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  55-63     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Coronary Disease / drug therapy*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Prospective Studies
Syndrome
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The use of brachytherapy to treat renal artery in-stent restenosis.
Next Document:  Evaluating a family-centred intervention for infant sleep problems.